Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2019-04-24
2019-04-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Part A will randomly compare three different doses of botulinum toxin type A (abobotulinumtoxin A) for the treatment of upper anterior gummy smile with larger gingival exposure (\> 4 mm).
Part B will assign one of two doses of botulinum toxin type A for participants with smaller gingival exposure (\< 4 mm).
Follow-up visits with photography will occur 4 and 12 weeks after their treatment. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.
This study is a pilot study designed to determine feasibility of this procedure.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2.5 U dose
Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
1. 2.5 U
2. 5 U
3. 7.5 U
Botulinum toxin type A
Participants will be randomized to one of three botulinum toxin type A doses.
5 U dose
Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
1. 2.5 U
2. 5 U
3. 7.5 U
Botulinum toxin type A
Participants will be randomized to one of three botulinum toxin type A doses.
7.5 U dose
Participants with more than 4 mm of upper anterior gingival exposure measured from the central incisor tooth will be randomly assigned (1:1:1) to receive different doses of botulinum toxin type A (abobotulinumtoxin A) on the levator labii superioris alaeque nasi as follows:
1. 2.5 U
2. 5 U
3. 7.5 U
Botulinum toxin type A
Participants will be randomized to one of three botulinum toxin type A doses.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum toxin type A
Participants will be randomized to one of three botulinum toxin type A doses.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Males or females ≥ 18 years old
3. Anterior gingival exposure during smiling larger than 4 mm measured from the central incisor tooth (part A), or 2-4 mm (part B).
4. Subjects of childbearing potential who present a negative urine pregnancy test at baseline and use an effective contraceptive method.
5. Subjects are in good health as judged by the investigator.
6. Subjects who are willing and have the ability to understand and provide informed consent for participation in the study and are able to communicate with the investigator.
Exclusion Criteria
2. Subjects participating in other clinical trials
3. Any prior surgery affecting the area of study
4. Subjects with neoplastic, muscular or neurological disease
5. Subjects who have received botulinum toxin treatment for gummy smile in the previous 12 months before the inclusion date
6. Subjects who have received Botulinum toxin treatment for any other cosmetic indication in the previous 6 months before the inclusion date
7. Subjects using aminoglycosides and penicillamine antibiotics, quinine or calcium channel blockers
8. Subjects with inflammation or active infection in the area to be injected
9. Subjects with history of sensitivity to the components of the formulation.
10. Uncooperative patients or patients with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations.
11. Subjects who are unable to understand the protocol or give informed consent.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Murad Alam
Professor in Dermatology, Otolaryngology-Head and Neck Surgery, and Surgery
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Murad Alam, MD
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northwestern University Department of Dermatology
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU00205065
Identifier Type: -
Identifier Source: org_study_id